Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Itolizumab is a first-in-class monoclonal antibody that selectively targets the CD6-ALCAM pathway. Patients enrolled in EQUINOX trial will be randomized 1:1 to receive either itolizumab or placebo in addition to best supportive care for the treatment for Covid-19.
Lead Product(s): Itolizumab
Therapeutic Area: Infections and Infectious Diseases Product Name: EQ001
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Equillium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020